• DARPA and JPEO Award Contract to SmartPharm, a Subsidiary of Sorrento, for Development of Rapid Countermeasure Against COVID-19 Using Gene-Encoded Neutralizing Antibodies

    1 month ago - By San Diego Biotechnology

    SAN DIEGO, Nov. 27, 2020 - SmartPharm Therapeutics, Inc. , a wholly-owned subsidiary of Sorrento Therapeutics, Inc. , and developer of next-generation, non-viral gene therapy technologies, ann......
    Read more ...